Tiffany N Long, Age 48Orlando, FL

2009005, Feb 26, 2009

May 2, 2006

11/913535

Peter W. Laird - South Pasadena CA, US
KImberly D. Siegmund - San Marino CA, US
Mihaela Campan - Los Angeles CA, US
Daniel J. Weisenberg - Playa del Rey CA, US
Tiffany I. Long - Chino CA, US

University of Southern California - Los Angles CA

C12Q 1/68
C12Q 1/02
G01N 33/53
C07H 21/00

435 6, 435 29, 435 71, 435 792, 536 2431

Particular aspects confirm the existence of a CpG island methylator phenotype (CIMP) in colorectal cancer, and provide novel validated DNA methylation markers associated with CIMP. Additional aspects provide novel methods and compositions for: determining CIMP status in colorectal cancers, determining the relationship between CIMP status and other molecular features of the cancers (e.g., BRAF mutation, KRAS mutation and MSI status); determining the relationship between CIMP status and other variables (e.g., age, sex, tumor location, family history, race, country of origin, tumor characteristics (including, tumor type, tumor grade, invasive margin characteristics, lymphocyte infiltration characteristics, direct spread, lymph node spread, venous spread and type of residual adjacent polyp, if present)); and determining, between subgroups defined by CIMP status and BRAF mutations, effects of selected risk factors (e.g., body mass index, smoking history, alcohol intake, dietary folate intake, folate metabolic enzyme polymorphisms and history of hormonal use).

2009012, May 14, 2009

Nov 10, 2005

11/719033

Peter W. Laird - South Pasadena CA, US
Daniel J. Weisenberger - Playa Del Rey CA, US
Mihaela Campan - Los Angeles CA, US
Tiffany I. Long - Chino CA, US

UNIVERSITY OF SOUTHERN CALIFORNIA - Los Angeles CA

C12Q 1/68

435 6

Preferred aspects provide novel high-throughput, sensitive methods (e.g., real-time PCR-based (MethyLight™) reactions) for detection and/or measurement of global genomic 5-methylcytosine content, based on measurement of DNA methylation of Alu, LINE-1 repetitive sequences, and the chromosome 1 centromeric satellite alpha and juxtacentromeric satellite 2 repeat sequences. Additional aspects provide sensitive methods for determining the amount of a DNA (e.g., in formalin-fixed, paraffin-embedded tissues). Combined (mean) use of Alu and Sat2 repeat methylation measurements provides for a surprisingly close correlation with global genomic 5-methylcytosine content measurements obtained by HPLC. Methylation of Alu repeats was determined to be closely associated with HPLC-based global methylation levels, as was methylation of satellite 2 and LINE-1 global genomic 5-methylcytosine content. The assays provide surrogate markers for global genomic 5-methylcytosine content analyses, and have substantial utility for high-throughput and population-based studies (e.g., genetic and dietary influences on global DNA methylation, folate deficiency, MTHFR gene polymorphisms, etc).

2012021, Aug 30, 2012

Feb 3, 2012

13/366192

Peter W. Laird - South Pasadena CA, US
Kimberly D. Siegmund - San Marino CA, US
Mihaela Campan - Los Angeles CA, US
Daniel J. Weisenberger - Playa del Rey CA, US
Tiffany I. Long - Chino CA, US

University of Southern California - Los Angeles CA

C12Q 1/68
C07H 21/04
G01N 33/574

435 611, 436501, 536 231

Particular aspects confirm the existence of a CpG island methylator phenotype (CIMP) in colorectal cancer, and provide novel validated DNA methylation markers associated with CIMP. Additional aspects provide novel methods and compositions for: determining CIMP status in colorectal cancers, determining the relationship between CIMP status and other molecular features of the cancers (e.g., BRAF mutation, KRAS mutation and MSI status); determining the relationship between CIMP status and other variables (e.g., age, sex, tumor location, family history, race, country of origin, tumor characteristics (including, tumor type, tumor grade, invasive margin characteristics, lymphocyte infiltration characteristics, direct spread, lymph node spread, venous spread and type of residual adjacent polyp, if present)); and determining, between subgroups defined by CIMP status and BRAF mutations, effects of selected risk factors (e.g., body mass index, smoking history, alcohol intake, dietary folate intake, folate metabolic enzyme polymorphisms and history of hormonal use).

2016028, Oct 6, 2016

Mar 9, 2016

15/065782

- Los Angeles CA, US
Kimberly D. Siegmund - San Marino CA, US
Mihaela Campan - Los Angeles CA, US
Daniel J. Weisenberger - Playa del Rey CA, US
Tiffany I. Long - Chino CA, US

C12Q 1/68

Particular aspects confirm the existence of a CpG island methylator phenotype (CIMP) in colorectal cancer, and provide novel validated DNA methylation markers associated with CIMP. Additional aspects provide novel methods and compositions for: determining CIMP status in colorectal cancers, determining the relationship between CIMP status and other molecular features of the cancers (e.g., BRAF mutation, KRAS mutation, and MSI status); determining the relationship between CIMP status and other variables (e.g., age, sex, tumor location, family history, race, country of origin, tumor characteristics (including, tumor type, tumor grade, invasive margin characteristics, lymphocyte infiltration characteristics, direct spread, lymph node spread, venous spread, and type of residual adjacent polyp, if present)); and determining, between subgroups defined by CIMP status and BRAF mutations, effects of selected risk factors (e.g., body mass index, smoking history, alcohol intake, dietary folate intake, folate metabolic enzyme polymorphisms, and history of hormonal use).